遗传 ›› 2015, Vol. 37 ›› Issue (5): 473-479.doi: 10.16288/j.yczz.15-001

• 研究报告 • 上一篇    下一篇

生物法合成伤寒O-糖蛋白结合疫苗及其免疫原性评估

彭哲慧1,2,潘超2,孙鹏2,冯尔玲2,吴军2,朱力2,彭清忠1,王恒樑2   

  1. 1. 吉首大学生物资源与环境科学学院,湖南吉首 416000;
    2. 军事医学科学院生物工程研究所,病原微生物生物安全国家重点实验室,北京 100071
  • 收稿日期:2015-01-25 出版日期:2015-05-20 发布日期:2015-05-20
  • 通讯作者: 彭清忠,教授,研究方向:微生物制药。E-mail: qzpengjsu@163.com;王恒樑,研究员,研究方向:病原微生物。E-mail: wanghl@bmi.ac.cn
  • 作者简介:彭哲慧,硕士研究生,专业方向:病原微生物。E-mail: michel121@126.com
  • 基金资助:
    国家自然科学基金项目(编号:81373316)资助

Preparation and immunogenicity-evaluation of typhoid O-specific polysaccharides bio-conjugate vaccines

Zhehui Peng1, 2, Chao Pan2, Peng Sun2, Erling Feng2, Jun Wu2, Li Zhu2, Qingzhong Peng1, Hengliang Wang2   

  1. 1. College of Biology and Environmental Sciences, Jishou University, Jishou 416000, China;
    2. State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Biotechnology, Beijing 100071, China
  • Received:2015-01-25 Online:2015-05-20 Published:2015-05-20

摘要: 伤寒由伤寒沙门氏菌(Salmonella Typhi)引发,至今在发展中国家仍是备受关注的重要公共卫生问题。文章通过敲除伤寒菌脂多糖合成途径中O-抗原连接酶基因,转入含脑膜炎奈瑟球菌(Neisseria meningitidis)蛋白糖基化途径中糖基转移酶的表达载体,以及改构的重组铜绿假单胞菌(Pseudomonas Aeruginosa)外毒素A(rEPAN29)的表达载体,使细胞内能够诱导合成以伤寒O特异性多糖(O-specific polysaccharides, OPS)为目标抗原、以rEPAN29为载体蛋白的伤寒OPS-rEPAN29糖蛋白复合物,并对纯化所得复合物进行了免疫原性评价。ELISA测定血清抗体滴度表明,rEPAN29作为载体蛋白能有效增加糖链的免疫原性,糖蛋白比单独的多糖能诱导产生更好的免疫应答;3次免疫、间隔3周比间隔2周IgG滴度稍有提高;而免疫过量的糖蛋白,抗O-多糖的血清抗体效价并无提升。文章为生物法制备多糖-蛋白结合疫苗提供了新思路,理论上也适用于其他革兰氏阴性菌的疫苗研发。

关键词: 结合疫苗, 伤寒沙门氏菌, 合成生物学, 重组EpA, O-多糖抗原

Abstract: Typhoid fever caused by Salmonella Typhi is still a major public health problem in developing countries. In this study, we constructed a genetically modified Salmonella Typhi strain expressing O-specific polysaccharides (OPS) antigen conjugated to a carrier, recombinant Pseudomonas aeruginosa exotoxin A(rEPA N29). The conjugates (OPS-rEPA N29) were further purified and evaluated for their immunogenicity. The results of ELISA showed that the conjugates evoked higher titers of IgG than OPS, suggesting that rEPAN29 increased immunogenicity of OPS significantly as a carrier. Moreover, three injections with 3-week interval evoked slightly higher titers of IgG than three injections with 2-week interval. However, injection of excess conjugates could not evoke higher titers of IgG against lipid polysaccharide (LPS). In summary, our study provides a new strategy for preparing polysaccharides-protein conjugate vaccines as well as similar bio-conjugate vaccines of other Gram-negative pathogens.

Key words: conjugate vaccine, Salmonella Typhi, synthetic biology, rEPA, O-polysaccharide antigen